CDCA3表达是非小细胞肺癌的预后生物标志物和潜在治疗靶点
本研究通过生物信息学、Western blot和组织芯片免疫组化分析CDCA3在非小细胞肺癌(NSCLC)中的表达,并用小干扰RNA在3株永生化人支气管上皮细胞(HBEC)系和7株NSCLC细胞系中敲低CDCA3进行体外功能实验。结果发现CDCA3转录本在NSCLC中较非恶性组织高度升高,高表达与患者预后差相关,敲低CDCA3可显著抑制所有NSCLC细胞系增殖并诱导G2/M期阻滞、p53非依赖性p21上调和细胞衰老。
要点
- CDCA3转录本在NSCLC中较非恶性组织高度升高,高表达与患者预后差相关。
- CDCA3蛋白在NSCLC组织中升高且表达局限于肿瘤细胞。
- 敲低CDCA3可显著抑制所有NSCLC细胞系增殖,诱导G2/M期阻滞和细胞衰老。
核心结论
- CDCA3是NSCLC的预后因素和潜在新治疗靶点,通过抑制肿瘤生长和促进肿瘤衰老发挥作用。
研究设计与样本
- 研究采用生物信息学、配对肿瘤与正常组织的Western blot分析及组织芯片免疫组化检测CDCA3在鳞状和非鳞状NSCLC中的表达。
- 使用小干扰RNA在3株永生化人支气管上皮细胞(HBEC)系和7株NSCLC细胞系中敲低CDCA3,通过多种体外实验确定其功能。
主要发现
- CDCA3转录本在NSCLC中较非恶性组织高度升高,高表达与患者预后差相关。
- CDCA3蛋白在NSCLC组织中升高且表达局限于肿瘤细胞。
- CDCA3在NSCLC细胞系中的表达较3株HBEC系同样升高。
- 在HBEC系中敲低CDCA3不影响细胞增殖,但敲低CDCA3表达显著降低所有NSCLC细胞系的增殖。
- 敲低CDCA3导致G2/M期细胞周期进程缺陷、p53非依赖性p21上调和细胞衰老诱导。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: NSCLC is the leading cause for cancer-related deaths worldwide. New therapeutic targets are needed, as development of resistance to current treatment, such as platinum-based chemotherapy, is inevitable. The purpose of this study was to determine the functional relevance and therapeutic potential of cell division cycle associated 3 protein (CDCA3) in NSCLC. METHODS: The expression of CDCA3 in squamous and nonsquamous NSCLC was investigated by using bioinformatics, Western blot analysis of matched tumor and normal tissue, and immunohistochemistry of a tissue microarray. The function of CDCA3 in NSCLC was determined by using several in vitro assays with small interfering RNA depleting CDCA3 in a panel of three immortalized human bronchial epithelial cell (HBEC) lines and seven NSCLC cell lines. RESULTS: In this study, cell division cycle associated 3 gene (CDCA3) transcripts were identified as highly increased in NSCLC versus in nonmalignant tissue, with high levels of CDCA3 being associated with poor patient prognosis. CDCA3 protein was also increased in NSCLC tissue and expression was limited to tumor cells. CDCA3 expression was similarly increased in a panel of NSCLC cell lines compared with in three HBEC lines. Although depletion of CDCA3 in the HBEC lines did not affect cellular proliferation, depletion of CDCA3 expression markedly reduced the proliferation of all NSCLC cell lines. CDCA3 depletion caused a defective G2/M-phase cell cycle progression, upregulation of p21 independent of p53, and induction of cellular senescence. CONCLUSIONS: Our findings highlight CDCA3 as a prognostic factor and potential novel therapeutic target in NSCLC through inhibition of tumor growth and promotion of tumor senescence.
引用
- Adams MN, Burgess JT, He Y, et al. Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28487093. doi:10.1016/j.jtho.2017.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。